Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 574Treatment of Major DepressionElectroconvulsive Therapy StudiesAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial

Rosenbaum, Jerrold F, Fava, Maurizio, Hoog, Sharon L, Ascroft, Richard C, Krebs, William B·1998·Biological Psychiatry

Abstract

Background Recent reports describe discontinuation-emergent adverse events upon cessation of selective serotonin reuptake inhibitors including dizziness, insomnia, nervousness, nausea, and agitation. We hypothesized that interruption of fluoxetine treatment would be associated with fewer discontinuation-emergent adverse events than interruption of sertraline or paroxetine treatment, based on fluoxetine's longer half-life. Methods In this 4-week study, 242 patients with remitted depression receiving maintenance therapy with open-label fluoxetine, sertraline, or paroxetine for 4-24 months had their maintenance therapy interrupted with double-blind placebo substitution for 5-8 days. The Symptom Questionnaire (SQ), the Discontinuation-Emergent Signs and Symptoms checklist, the 28-item Hamilton Depression Rating Scale, and the Montgomery-Asberg Depression Rating Scale were used to assess somatic distress and stability of antidepressant response. Results Two hundred twenty patients (91%) completed the study. Following interruption of therapy, fluoxetine-treated patients experienced fewer discontinuation-emergent events than either sertraline-treated or paroxetine-treated patients (p Conclusions Abrupt interruption of antidepressant therapy for 5-8 days was associated with the emergence of new somatic and psychological symptoms in patients treated with paroxetine and to a lesser degree sertraline, with few symptoms seen with fluoxetine.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0006-3223(98)00126-7

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 40 references

Research works printed but not linked: 3

  1. Bhaumik, 1996, Treatment outcomes including withdrawal phenomena with fluoxetine and paroxetine in patients with learning disabilities suffering from affective disorders [letter], Hum Psychopharmacol, 11, 337
  2. Olivier-Martin, 1986, Facteurs psychologiques, observance et resistance aux traitements antidepresseurs (Psychological factors, compliance and resistance to antidepressant treatment) (abstract in English), Encephale, 12, 197
  3. Young, 1986, Medication noncompliance in schizophrenia, Bull Am Acad Psychiatry Law, 14, 105

Cited by

See all 574

Metadata

Authors
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B.
Affiliations
  • Massachusetts General Hospital (US)
  • Eli Lilly (United States) (US)
Corresponding author
Rosenbaum, Jerrold F
Venue
Biological Psychiatry
Publisher
Elsevier BV
Published
1998-07
Volume
44
Issue
2
Pages
77-87
ISSN
0006-3223 (ISSN-L)
OpenAlex
W2022191212
Cited by
574
References
40
Citations by year
2026: 27 · 2025: 25 · 2024: 25 · 2023: 22 · 2022: 19 · 2021: 22 · 2020: 22 · 2019: 26 · 2018: 13 · 2017: 12 · 2016: 14 · 2015: 19 · 2014: 11 · 2013: 16 · 2012: 16
FWCI
16.36
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
selective serotonin reuptake inhibitors, antidepressant discontinuation syndrome, fluoxetine, sertraline, paroxetine, remitted depression, drug discontinuation, elimination half-life
MeSH terms
Adult, Depressive Disorder, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Fluoxetine, Half-Life, Health Status, Humans, Male, Middle Aged, Placebos, Prospective Studies, Psychiatric Status Rating Scales, Surveys and Questionnaires, Serotonin, Substance Withdrawal Syndrome, 1-Naphthylamine, Selective Serotonin Reuptake Inhibitors, Paroxetine, Sertraline

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. https://app.cochat.ai/papers/10.1016/s0006-3223(98)00126-7
The paper
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998). Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biological Psychiatry. https://doi.org/10.1016/s0006-3223(98)00126-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.